Botteman Marc
Pharmerit North America LLC, 7272 Wisconsin Ave, Suite 300, Bethesda, MD 20814, USA.
Sleep Med. 2009 Sep;10 Suppl 1:S22-5. doi: 10.1016/j.sleep.2009.07.001. Epub 2009 Jul 31.
Chronic primary insomnia is a major public health problem causing significant burden for those affected. Rising health care costs may cause increased financial pressures on governments and private payers, forcing stricter cost-control measures and, as a result, insomnia, often considered a lifestyle condition, may not receive the proper attention it deserves. In order to highlight the benefits that can be achieved through successful treatment of insomnia, there is a need for further comparative studies of existing and emerging treatments, cost burden of illness and cost-effectiveness analyses. Health economic assessment of insomnia and its treatments is an emerging area. The development of comprehensive assessment of insomnia treatments, however, has been hindered by complexities and gaps in the available data. Health economic models of insomnia, such as the one detailed here, should enable researchers to better address the effects of different treatments on clinical and economic measures for insomnia and related comorbidities. It is apparent that research into the cost-effectiveness of therapies for insomnia is in its infancy and further work is needed.
慢性原发性失眠是一个重大的公共卫生问题,给患者带来了沉重负担。不断上涨的医疗保健成本可能会给政府和私人支付方带来更大的财政压力,迫使采取更严格的成本控制措施,结果,失眠这种通常被视为生活方式问题的疾病可能得不到应有的适当关注。为了突出成功治疗失眠所能带来的益处,有必要对现有和新出现的治疗方法、疾病成本负担以及成本效益分析进行进一步的比较研究。失眠及其治疗方法的卫生经济评估是一个新兴领域。然而,现有数据的复杂性和差距阻碍了对失眠治疗方法进行全面评估的发展。失眠的卫生经济模型,比如本文详细介绍的这种模型,应能使研究人员更好地探讨不同治疗方法对失眠及相关合并症的临床和经济指标的影响。显然,对失眠治疗方法的成本效益研究尚处于起步阶段,还需要开展更多工作。